Cite
MLA Citation
Z. Zhuang et al.. “PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA.” HemaSphere, vol. 6, n.d., pp. 1909–1910. http://access.bl.uk/ark:/81055/vdc_100158013638.0x000025